Therapy Detail

Therapy Name M2698
Synonym
Therapy Description

M2698 (MSC2363318A) binds to and inhibits the activity of P70S6K and AKT, which prevents the activation of the PI3K/AKT/P70S6K signaling pathway, thereby inhibiting tumor cell proliferation (PMID: 27186432).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
M2698 MSC2363318A Akt Inhibitor (Pan) 17 S6 Kinase Inhibitor 5 M2698 (MSC2363318A) binds to and inhibits the activity of P70S6K and AKT, which prevents the activation of the PI3K/AKT/P70S6K signaling pathway, thereby inhibiting tumor cell proliferation (PMID: 27186432).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
PTEN loss triple-receptor negative breast cancer sensitive M2698 Preclinical - Cell line xenograft Actionable In a preclinical study, a triple-receptor negative breast cancer xenograft model harboring PTEN loss was sensitive to M2698 (MSC2363318A), demonstrating inhibition of tumor growth and tumor regression (PMID: 27186432). 27186432
Unknown unknown Advanced Solid Tumor not applicable M2698 Phase I Actionable In a Phase I trial, M2698 (MSC2363318A) demonstrated safety and preliminary efficacy in a variety of advanced solid tumor patients (Ann. Oncol. 26 (Suppl 2): ii25-ii27, 2015). detail...
Unknown unknown Advanced Solid Tumor not applicable M2698 Phase I Actionable In a Phase I trial, M2698 (MSC2363318A) demonstrated safety and preliminary efficacy, with 19% (6/32) of advanced solid tumor patients remained on treatment for more than 180 days (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 370PD; NCT01971515). detail...
Unknown unknown Advanced Solid Tumor not applicable M2698 Preclinical Actionable In a preclinical study, MSC2363318A demonstrated sustained inhibition of S6K phosphorylation, and inhibited tumor growth in several human cancer xenograft models of breast, pancreatic, glioblastoma and ovarian cancers (Mol Cancer Ther 2013;12(11 Suppl):A162). detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT01971515 Phase I M2698 First-in-Human Dose Escalation Trial in Subjects With Advanced Malignancies Completed